Fremanezumab
Biological
Teva Pharmaceuticals USA, Inc.
Total Payments
$24.5M
Transactions
1,037
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $24.5M | 1,037 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24.5M | 1,037 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TV48125-CNS-30049/50/51 | Teva Pharmaceuticals USA, Inc. | $13.1M | 3 |
| TV48125-CNS | Teva Pharmaceuticals USA, Inc. | $6.9M | 4 |
| TV48125-BE-10114 | Teva Pharmaceuticals USA, Inc. | $3.1M | 0 |
| TV48125-CNS-30056/57/58 | Teva Pharmaceuticals USA, Inc. | $1.0M | 2 |
| TV48125-PK-10078 | Teva Pharmaceuticals USA, Inc. | $355,349 | 0 |
| TV48125-CNS-30068 | Teva Pharmaceuticals USA, Inc. | $49,733 | 0 |
| The Use of Computer-Assisted Headache Diagnosis to Improve Recognition of Migraine and Chronic Migraine in Primary Care | Teva Pharmaceuticals USA, Inc. | $20,851 | 0 |
| TV48125-CNS-20024 | Teva Pharmaceuticals USA, Inc. | $5,700 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $24.5M
- Total Doctors 4
- Transactions 1,037
About Fremanezumab
Fremanezumab is a biological associated with $24.5M in payments to 4 healthcare providers, recorded across 1,037 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $24.5M was paid across 1,037 transactions to 4 doctors.
The most common payment nature for Fremanezumab is "Unspecified" ($24.5M, 100.0% of total).
Fremanezumab is associated with 8 research studies, including "TV48125-CNS-30049/50/51" ($13.1M).